Article

Bill Pushes Legislation to Restore Medicare Funding for Cancer Treatments

A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels

A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels. Because cancer treatment regimens are costly, they have been highly affected by the sequester cuts. ACCC Buzz reports:

After a recent hearing by the House Energy and Commerce Health Subcommittee, the Cancer Patient Protection Act of 2013 (HR 1416) is gaining support. The bi-partisan bill was introduced by Congresswoman Renee Ellmers and now enjoys 97 co-sponsors.

Our fight is not over, however. ACCC continues to educate other members of the House about the importance of this legislation. ACCC recently met with Representative Erik Paulsen’s office, who is one of the latest members to sign onto HR 1416. We are continuing to work to identify a champion in the Senate.

Read the full story here: http://bit.ly/15mNCLo

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Merrill H. Stewart, MD
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo